Michael Kauffman is currently the Chief Medical Officer of Proteolix, Inc. in San Francisco, California. He was formerly CEO and President of Epix Pharmaceuticals (formerly Predix Pharmaceuticals) — a privately held U.S. company specializing in new drug discovery, screening, and biological modeling integrated with traditional medicinal chemistry.
Prior to joining Epix, Michael was Vice President of Medicine and leader of the VELCADE Development Program at Millennium Pharmaceuticals, Inc. He also held senior positions at Millennium Predictive Medicine, Inc. and Biogen Corporation. Michael is the author of numerous medical publications and is the publisher and president of OutlineMed Inc., a developer of medical information software. In January 2004, he joined the board of Bioenvision (BIV, Amex), a company that seeks to develop and distribute cancer treatment drugs and technologies.
Michael received his B.A. in Biochemistry summa cum laude from Amherst College in 1985 and his M.D. and Ph.D. in molecular biology from Johns Hopkins Medical School in 1992. He performed his postdoctoral training at Massachusetts General Hospital and Beth Israel Hospital, both part of the Harvard Medical School system. Michael is a member of the 2004 class of Henry Crown Fellows at the Aspen Institute.